ARCH Arch Biopartners Inc.

0.6152USD0.8800 CAD · TSXV-6.38%Mkt Cap: 41.79M USDP/E: —

Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which i…

Key Statistics

Company
Market Cap41.79M USD
Enterprise Value46.54M USD
Revenue (TTM)0 USD
Gross Profit-519.97K USD
Net Income (TTM)-1.09M USD
Revenue/Share0.00 USD
Last Price0.6152 USD
Fiscal Year EndSep 2025
MR QuarterJun 2026
Employees—
CountryCA
SectorHealthcare
IndustryBiotechnology
ISINCA03938C1041
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/SInfinity
P/B-14.92
EPS (TTM)-0.03 USD
EPS (Forward)—
52W Range
0.272646% of range1.014
52W High1.014 USD
52W Low0.2726 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE40.00%
ROA-1485.45%
ROIC—
ROCE—
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.20M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-1.26%
Net Debt1.90M USD
Net Debt/EBITDA—
Net Debt/FCF—
Balance Sheet
Debt/Equity-0.64
Current Ratio0.01
Quick Ratio0.01
Book Value/Sh-0.04 USD
Cash/Share0.00 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateSep 13, 2000
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.67.93M
Float53.82M
Insiders18.04%
Institutions0.00%
Short Interest
Short Ratio0.1d
Short % Out.0.00%
Shares Short1.74K
Short (prev mo.)3.21K
Technical
SMA 500.6098 (+0.9%)
SMA 2000.5341 (+15.2%)
Beta1.61
S&P 52W Chg12.00%
Avg Vol (30d)29.96K
Avg Vol (10d)19.43K
Technical Indicators
RSI (14)48.6
MACD0.0178
MACD Signal0.0148
MACD Hist.+0.0030
BB Upper0.7001 USD
BB Middle0.6197 USD
BB Lower0.5393 USD
BB Width25.95%
ATR (14)0.0436 USD
Vol Ratio (20d)0.69x

About Arch Biopartners (CVE: ARCH)

›

Arch Biopartners (CVE: ARCH) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.

The shares were at 0.8800 CAD on 19 November 2026, down 10.2% over 52 weeks. Its 52-week range is 0.3900 CAD to 1.450 CAD: the price is 39.3% below the high and 125.6% above the low.

Its market capitalisation is 59.78M CAD.

Arch Biopartners reports return on equity of 40.0% and an operating margin of 0.0%.

Its debt exceeds its cash by 2.72M CAD. Its Piotroski F-score is 0 out of 9, a weak reading of its financial health. The next earnings report is expected on 28 January 2027.